Nebenwirkungen · Jyseleca
Jyseleca 100 mg film-coated tablets Jyseleca 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-144387 · Präparat HOS-099170
Across the two placebo-controlled induction studies, the frequency of serious infections was 0.6% in the filgotinib 200 mg group, 1.1% in the filgotinib 100 mg group, and 1.1% in the placebo group. In the placebo-controlled maintenance study, the frequency of serious infections in the filgotinib 200 mg group was 1%, compared to 0% in the respective placebo group. In the maintenance study filgotinib 100 mg group, the frequency of serious infections was 1.7%, compared with 2.2% in the respective placebo group.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-10T15:54:00Z · SHA-256 4442cfcdd2007795a9b4a5f2ba8b8acde0a07629686c5967414dd017b37ddace · Passage 680dd83c1d2a4e82249128ceebaaf23ef3fada6be77a4a01a76a604373b0d2bf · Zeichen 5959–6472 im Abschnitt